Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 11/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.34 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.34 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3600643 | 1.00 | TRPV1 (0.40) | TRPV1ALDH1A1SMN1; SMN2CYSLTR2CYSLTR1 | |
| SCHEMBL3604162 | 0.93 | TRPV1 (0.40) | TRPV1ALDH1A1SMN1; SMN2CYSLTR2CYSLTR1 | |
| SCHEMBL3604164 | 0.93 | TRPV1 (0.40) | TRPV1ALDH1A1SMN1; SMN2CYSLTR2CYSLTR1 | |
| SCHEMBL3605280 | 0.93 | TRPV1 (0.40) | TRPV1ALDH1A1SMN1; SMN2CYSLTR2CYSLTR1 | |
| SCHEMBL3599796 | 0.93 | TRPV1 (0.36) | TRPV1ALDH1A1SMN1; SMN2CYSLTR2CYSLTR1 | |
| SCHEMBL3599799 | 0.93 | TRPV1 (0.36) | TRPV1ALDH1A1SMN1; SMN2CYSLTR2CYSLTR1 | |
| SCHEMBL3605282 | 0.93 | TRPV1 (0.40) | TRPV1ALDH1A1SMN1; SMN2CYSLTR2CYSLTR1 | |
| SCHEMBL3594177 | 0.92 | TRPV1 (0.42) | TRPV1ALDH1A1SMN1; SMN2KCNQ2MAPT | |
| SCHEMBL3594179 | 0.92 | TRPV1 (0.42) | TRPV1ALDH1A1SMN1; SMN2KCNQ2MAPT | |
| SCHEMBL3597684 | 0.86 | CYSLTR2 (0.37) | TRPV1ALDH1A1SMN1; SMN2CYSLTR2CYSLTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2128157-A1 | HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | CCNY, CCND3, NSD3 | TRPV1 2518/4885ALDH1A1 1904/4885SMN1; SMN2 1047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.